Product Name: ABT-869 (Linifanib) | KDR, CSF-1R, FLT1/3, PDGFRb inhibitor
Product Description: ABT-869 (Linifanib) is an aminobenzopyrazole-based, orally available, ATP-competitive receptor tyrosine kinase inhibitor with IC50 potency against KDR, FLT1, CSF-1R, FLT3, and PDGFRb of 4 nM, 3 nM, 3 nM, 4 nM, and 66 nM, respectively. It is highly selectiWeb Site：Medchemexpress
Chemical Formula: C21H18FN5O
Molecular Weight: 375.41
‘&“CAS NO: 1403254-99-8 EPZ-6438
Purity: 98%
Appearance: White
Chemical Name: 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)ureaCytoskeleton inhibitors
Solubility: Up to 100 mM in DMSO
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage Condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/20498328
